CareDx, Inc (NASDAQ:CDNA) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | Safe Harbor Statement 2 These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including statements regarding the future fina ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-365 ...

GROWTH & CareDx 2024 INVESTOR DA OCTOBER 15, 2024 E CareDx UNLOCKING GROWTH SAFE HARBOR STATEMENT These slides, and the accompanying oral presentation, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, ar 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including statements regardi future financial position of CareDx", Inc. (together with its subsidiari ...

Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93. This places CDNA 5.77% below its 52-week high of $34.84 and 583.96% above its 52-week low of $4.80. Trading volume was 663,513 shares, 72.2% of the average daily volume of 918,408. Wall Street Analysts Forecast Based on the one-year price targets offered by 7 analysts, the average target price for CareDx Inc (CDNA, Fin ...

Since my last analysis, CareDx, Inc. (NASDAQ: CDNA ) has resolved its corporate instability and insurance coverage. It also seems to have progressed towards preventing further legal disputes with Natera ( NTRA ). This My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad ...

SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc. If you are a current owner of shares, contact leo@moka.law or call (619) 780-3993. CareDx, Inc. (NASDAQ: CDNA) Accused of Misleading Investors On September 18, 2024, Judge Trina L. Thompson of the United States District Court for the Northern District of Califor ...

Have you been paying attention to shares of CareDx (CDNA) ? Shares have been on the move with the stock up 73.7% over the past month. The stock hit a new 52-week high of $27.47 in the previous session. CareDx has gained 128.3% since the start of the year compared to the 6.6% move for the Zacks Medical sector and the 4.1% return for the Zacks Medical Services industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus es ...

CareDx (CDNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The p ...

CareDx (CDNA) reported $92.27 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 31.3%. EPS of $0.25 for the same period compares to -$0.18 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $67.2 million, representing a surprise of +37.32%. The company delivered an EPS surprise of +292.31%, with the consensus EPS estimate being -$0.13. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...